Immucell (ICCC) Receivables - Other (2010 - 2026)

Immucell (ICCC) has reported Receivables - Other for 17 consecutive years, with $6354.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other fell 85.85% year-over-year to $6354.0; the trailing twelve-month figure through Jun 2026 stood at $6354.0 (down 85.85% YoY), and the FY2025 full-year result was $31177.0, down 23.12% from the prior year.
• Receivables - Other declined to $6354.0 in Q2 2026 per ICCC's latest filing, from $31177.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $5.1 million in Q1 2022 and bottomed at $6354.0 in Q2 2026.
• Historically, Receivables - Other has averaged $1.2 million across 5 years, with a median of $44913.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other soared 5790.1% in 2022, then plunged 99.55% in 2023.
• Over 5 years, Receivables - Other stood at $42178.0 in 2022, then retreated by 5.8% to $39733.0 in 2023, then gained by 2.07% to $40555.0 in 2024, then retreated by 23.12% to $31177.0 in 2025, then plunged by 79.62% to $6354.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $6354.0, $31177.0, and $54341.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.